Iradimed (IRMD) Depreciation & Amortization (CF) (2013 - 2026)

Iradimed (IRMD) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $455000.0 in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $455000.0, up 134.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (up 81.57% YoY), and the FY2025 annual result was $1.2 million, up 42.54% from the prior year.
• Depreciation & Amortization (CF) climbed to $455000.0 in Q1 2026 per IRMD's latest filing, from $380680.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $494176.0 in Q2 2022 and troughed at -$692905.0 in Q4 2022.
• A 5-year average of $227932.5 and a median of $205375.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) sank 279.23% in 2022, then surged 134.54% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at -$692905.0 in 2022, then surged by 129.64% to $205375.0 in 2023, then fell by 4.95% to $195210.0 in 2024, then surged by 95.01% to $380680.0 in 2025, then grew by 19.52% to $455000.0 in 2026.
• Business Quant data shows IRMD's Depreciation & Amortization (CF) at $455000.0 in Q1 2026, $380680.0 in Q4 2025, and $383722.0 in Q3 2025.